




CLERK, U.S. BANKRUPTCY COURT  
NORTHERN DISTRICT OF TEXAS

**ENTERED**

THE DATE OF ENTRY IS ON  
THE COURT'S DOCKET

The following constitutes the ruling of the court and has the force and effect therein described.

Signed April 5, 2024

  
United States Bankruptcy Judge

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE NORTHERN DISTRICT OF TEXAS  
DALLAS DIVISION**

In re:  
  
EIGER BIOPHARMACEUTICALS, INC., *et al.*<sup>1</sup>  
  
Debtors.

Chapter 11  
  
Case No. 24-80040 (SGJ)  
  
(Jointly Administered)

**ORDER (I) AUTHORIZING THE DEBTORS TO  
(A) FILE A CONSOLIDATED CREDITOR MATRIX AND  
(B) FILE A CONSOLIDATED LIST OF 30 LARGEST UNSECURED  
CREDITORS; (II) WAIVING THE REQUIREMENT TO FILE A LIST OF EQUITY  
SECURITY HOLDERS; (III) AUTHORIZING THE DEBTORS TO REDACT CERTAIN  
PERSONALLY IDENTIFYING INFORMATION; AND (IV) APPROVING THE  
FORM AND MANNER OF NOTIFYING CREDITORS OF THE  
COMMENCEMENT OF THE CHAPTER 11 CASES  
AND OTHER INFORMATION**

<sup>1</sup> The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors' service address is 2155 Park Boulevard, Palo Alto, California 94306.

Upon the motion (“Motion”)<sup>2</sup> of the debtors and debtors in possession in the above-captioned chapter 11 cases (collectively, the “Debtors”), for entry of an order (this “Order”) (a) authorizing the Debtors to (i) file a consolidated creditor matrix and (ii) file a consolidated list of 30 largest unsecured creditors; (b) waiving the requirement to file a list of equity security holders; (c) authorizing the Debtors to redact personally identifying information from documents filed with the Court in these chapter 11 cases (including any creditor matrix, the schedules of assets and liabilities, and the statement of financial affairs); (d) approving the form and manner of notice of the commencement of these chapter 11 cases and other information; and (e) granting related relief, each as more fully set forth in the Motion; and upon consideration of the First Day Declaration; and this Court having jurisdiction over this matter pursuant to 28 U.S.C. § 1334; and this matter being a core proceeding within the meaning of 28 U.S.C. § 157(b)(2); and the Court being able to issue a final order consistent with Article III of the United States Constitution; and it appearing to the Court that venue of this proceeding and the Motion in this district is proper pursuant to 28 U.S.C. §§ 1408 and 1409;<sup>3</sup> and appropriate notice of and opportunity for a hearing on the Motion having been given; and the relief requested in the Motion being in the best interests of the Debtors’ estates, their creditors, and other parties in interest; and the Court having determined that the legal and factual bases set forth in the Motion establish just cause for the relief granted herein; and after due deliberation and sufficient cause appearing therefor, it is

**HEREBY ORDERED THAT:**

1. The Motion is granted on a final bases as set forth herein.

---

<sup>2</sup> Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Motion.

<sup>3</sup> Nothing in this Order shall preclude any later order of the Court approving a motion to transfer venue.

2. The Debtors are authorized, but not directed, to file a Consolidated Creditor Matrix and a Consolidated Top 30 Creditors List.

3. The requirement that Debtor Eiger BioPharmaceuticals, Inc. ("Eiger") file a list of equity security holders pursuant to Bankruptcy Rule 1007(a)(3) is waived.

4. Any requirement that Eiger provide notice directly to equity security holders under Bankruptcy Rule 2002(d) is waived, and the Debtors are authorized to serve the notices required under Bankruptcy Rule 2002(d) on the registered holders of Eiger equity securities and, to the extent they are known, on beneficial holders, through the appropriate broker, Depository Trust Company participant, or other intermediary. The Debtors will cause the notices required under Bankruptcy Rule 2002(d) to be served on registered holders of Eiger's common stock and to be published in full in *The New York Times* (National Edition) and the *San Francisco Chronicle* in the Debtors' business judgment.

5. The Debtors are authorized, but not directed, to redact names, home and email addresses, and any other personally identifying information of individuals or any other natural person listed from any document filed or to be filed with the Court in these chapter 11 cases; *provided*, that the Debtors shall provide unredacted versions of any such document filed with the Court and redacted in accordance with this Order to (a) the Court, (b) the U.S. Trustee, and (c) counsel to any statutory committee appointed in these chapter 11 cases upon a request to the Debtors (email being sufficient) or to the Court, subject to the restrictions of the UK GDPR and EU GDPR. The unredacted version of the matrix shall include a header, or any other reasonable notice, with language putting the party in interest on notice of this Court's Order, the redacted nature of the document and attaching this Order.

6. The Notice of Commencement in the form attached as **Exhibit 1** to this Order is approved. Within five (5) business days of the entry of this Order, the Debtors are authorized to serve the Notice of Commencement on all parties on the creditor matrix and publish the same, in a form modified for publication, in *The New York Times* (National Edition) and the *San Francisco Chronicle* within five (5) business days of entry of this Order. Service of the Notice of Commencement shall be deemed adequate and sufficient notice of: (a) the commencement of these chapter 11 cases and (b) the scheduling of the meeting of creditors under section 341 of the Bankruptcy Code.

7. Nothing herein precludes a party in interest's right to seek emergency relief from the provisions herein or file a motion requesting that the Court allow access to the information redacted by this Order.

8. Nothing contained in this Motion or Order shall be deemed or construed as directing or otherwise effecting a substantive consolidation of the Debtors' chapter 11 cases.

9. Notice of the Motion as provided therein shall be deemed good and sufficient notice of such Motion, and the requirements of Bankruptcy Rule 6004(a) and the Local Rules are satisfied by such notice.

10. The Debtors are authorized to take all such reasonable actions necessary to effectuate the relief granted in this Order in accordance with the Motion.

11. This Court retains exclusive jurisdiction with respect to all matters arising from or related to the implementation, interpretation, and enforcement of this Order.

**### END OF ORDER ###**

Submitted By:

**SIDLEY AUSTIN LLP**

Thomas R. Califano (TX Bar No. 24122825)  
William E. Curtin (*pro hac vice* pending)  
Anne G. Wallice (*pro hac vice* pending)  
787 Seventh Avenue  
New York, NY 10019  
Telephone: (212) 839-5300  
Facsimile: (212) 839-5599  
Email: tom.califano@sidley.com  
wcurtin@sidley.com  
anne.wallice@sidley.com

*and*

Charles M. Persons (TX Bar No. 24060413)  
2021 McKinney Avenue, Suite 2000  
Dallas, Texas 75201  
Telephone: (214) 981-3300  
Facsimile: (214) 981-3400  
Email: cpersons@sidley.com

*Proposed Attorneys for the Debtors and  
Debtors in Possession*

**Exhibit 1**

**Notice of Commencement**

<b>Information to identify the case:</b>		
Debtor Name	Eiger BioPharmaceuticals, Inc., et al.	EIN 33-0971591
United States Bankruptcy Court for the Northern District of Texas	Date Case Filed for chapter 11	04/01/2024
Case Number	24-80040 (SGJ)	

Official Form 309F1 (For Corporations or Partnerships)

**Notice of Chapter 11 Bankruptcy Case**

10/20

**For the debtor listed above, a case has been filed under chapter 11 of the Bankruptcy Code. An order for relief has been entered.**

**This notice has important information about the case for creditors and debtors, including information about the meeting of creditors and deadlines. Read both pages carefully.**

The filing of the case imposed an automatic stay against most collection activities. This means that creditors generally may not take action to collect debts from the debtor or the debtor's property. For example, while the stay is in effect, creditors cannot sue, assert a deficiency, repossess property, or otherwise try to collect from the debtor. Creditors cannot demand repayment from the debtor by mail, phone, or otherwise. Creditors who violate the stay can be required to pay actual and punitive damages and attorney's fees.

Confirmation of a chapter 11 plan may result in a discharge of debt. A creditor who wants to have a particular debt excepted from discharge may be required to file a complaint in the bankruptcy clerk's office within the deadline specified in this notice. (See line 11 below for more information.)

To protect your rights, consult an attorney. All documents filed in the case may be inspected at the bankruptcy clerk's office at the address listed below or through PACER (Public Access to Court Electronic Records at <https://pacer.uscourts.gov>), or by visiting the Debtors' case website at [www.kccllc.net/Eiger](http://www.kccllc.net/Eiger).

**The staff of the bankruptcy clerk's office cannot give legal advice.**

**Do not file this notice with any proof of claim or other filing in the case.**

<b>1. Debtor's full name</b>		See chart below	
<b>2. All other names used in the last 8 years</b>			
<b>Debtor</b>		<b>Other Name(s)</b>	
<b>Jointly Administered Cases:</b>			
<b>DEBTOR</b>	<b>ADDRESS</b>	<b>CASE NO.</b>	<b>EIN</b>
Eiger BioPharmaceuticals, Inc.	2155 Park Boulevard, Palo Alto, California 94306	24-80040 (SGJ)	33-0971591
EBPI Merger Inc.	2155 Park Boulevard, Palo Alto, California 94306	24-80041 (SGJ)	26-3679986
EB Pharma LLC	2155 Park Boulevard, Palo Alto, California 94306	24-80042 (SGJ)	61-1748352
Eiger BioPharmaceuticals Europe Limited	30 Upper High Street, Thame, Oxfordshire, OX9 3EZ United Kingdom	24-80043 (SGJ)	N/A
EigerBio Europe Limited	Room 002, 28-32 Pembroke Street Upper, Dublin 2, Ireland D02NT28 Ireland	24-80044 (SGJ)	N/A

<b>3. Address</b>	See chart above				
<b>4. Debtor's attorney (proposed)</b>  <table border="0" data-bbox="159 216 1312 506"><tr><td data-bbox="159 216 535 380"><b>Sidley Austin LLP</b> Thomas R. Califano (TX Bar No. 24122825) William E. Curtin (<i>pro hac vice</i> pending) Anne G. Wallace (<i>pro hac vice</i> pending) 787 Seventh Avenue New York, NY 10019</td><td data-bbox="959 216 1312 327"><b>Contact Phone:</b> (212) 839-5300 tom.califano@sidley.com wcurtin@sidley.com anne.wallice@sidley.com</td></tr><tr><td data-bbox="159 396 535 506"><b>Sidley Austin LLP</b> Charles M. Persons (TX Bar No. 24060413) 2021 McKinney Avenue, Suite 2000 Dallas, Texas 75201</td><td data-bbox="959 396 1312 453"><b>Contact Phone:</b> (214) 981-3300 cpersons@sidley.com</td></tr></table>		<b>Sidley Austin LLP</b> Thomas R. Califano (TX Bar No. 24122825) William E. Curtin ( <i>pro hac vice</i> pending) Anne G. Wallace ( <i>pro hac vice</i> pending) 787 Seventh Avenue New York, NY 10019	<b>Contact Phone:</b> (212) 839-5300 tom.califano@sidley.com wcurtin@sidley.com anne.wallice@sidley.com	<b>Sidley Austin LLP</b> Charles M. Persons (TX Bar No. 24060413) 2021 McKinney Avenue, Suite 2000 Dallas, Texas 75201	<b>Contact Phone:</b> (214) 981-3300 cpersons@sidley.com
<b>Sidley Austin LLP</b> Thomas R. Califano (TX Bar No. 24122825) William E. Curtin ( <i>pro hac vice</i> pending) Anne G. Wallace ( <i>pro hac vice</i> pending) 787 Seventh Avenue New York, NY 10019	<b>Contact Phone:</b> (212) 839-5300 tom.califano@sidley.com wcurtin@sidley.com anne.wallice@sidley.com				
<b>Sidley Austin LLP</b> Charles M. Persons (TX Bar No. 24060413) 2021 McKinney Avenue, Suite 2000 Dallas, Texas 75201	<b>Contact Phone:</b> (214) 981-3300 cpersons@sidley.com				
<b>5. Bankruptcy clerk's office</b>  Documents in this case may be filed at this address:  Earle Cabell Federal Building                      Hours open: Monday through Friday 8:30 a.m. – 4:30 p.m. 1100 Commerce St., Rm. 1254                      Contact phone: (214) 753-2000 Dallas, TX 75242-1496  You may inspect all records filed in this case at this office or online at <a href="https://pacer.uscourts.gov">https://pacer.uscourts.gov</a> , or by visiting the Debtors' case website at <a href="http://www.kccllc.net/Eiger">www.kccllc.net/Eiger</a> .					
<b>6. Meeting of creditors</b>  The debtor's representative must attend the meeting to be questioned under oath. Creditors may attend, but are not required to do so.  <b>Date:</b> May 13, 2024 at 1:30 p.m. CT <b>Location:</b> By telephone  Information can be found at the Debtors' case website, available at <a href="http://www.kccllc.net/Eiger">www.kccllc.net/Eiger</a> .  The meeting may be continued or adjourned to a later date. If so, the date will be on the court docket.					
<b>7. Proof of claim deadline</b>  <b>Deadlines for filing proof of claim:</b> To be determined. Additional information will be provided at a later date. Information can be found at the Debtors' case website, available at <a href="http://www.kccllc.net/Eiger">www.kccllc.net/Eiger</a> .  A proof of claim is a signed statement describing a creditor's claim. A proof of claim form may be obtained at <a href="http://www.uscourts.gov">www.uscourts.gov</a> or any bankruptcy clerk's office.  Your claim will be allowed in the amount scheduled unless: <ul style="list-style-type: none"><li>■ your claim is designated as <i>disputed</i>, <i>contingent</i>, or <i>unliquidated</i>;</li><li>■ you file a proof of claim in a different amount; or</li><li>■ you receive another notice.</li></ul> If your claim is not scheduled or if your claim is designated as <i>disputed</i> , <i>contingent</i> , or <i>unliquidated</i> , you must file a proof of claim or you might not be paid on your claim and you might be unable to vote on a plan. You may file a proof of claim even if your claim is scheduled.  You may review the schedules at the bankruptcy clerk's office or online at <a href="https://pacer.uscourts.gov">https://pacer.uscourts.gov</a> .  Secured creditors retain rights in their collateral regardless of whether they file a proof of claim. Filing a proof of claim submits a creditor to the jurisdiction of the bankruptcy court, with consequences a lawyer can explain. For example, a secured creditor who files a proof of claim may surrender important nonmonetary rights, including the right to a jury trial.					
<b>8. Exception to discharge deadline</b>  The bankruptcy clerk's office must receive a complaint and any required filing fee by the following deadline.	If § 523(c) applies to your claim and you seek to have it excepted from discharge, you must start a judicial proceeding by filing a complaint by the deadline stated below.  <b>Deadline for filing the complaint: To be Determined.</b>				



**9. Creditors with a foreign address** If you are a creditor receiving notice mailed to a foreign address, you may file a motion asking the court to extend the deadlines in this notice. Consult an attorney familiar with United States bankruptcy law if you have any questions about your rights in this case.

**10. Filing a Chapter 11 bankruptcy case** Chapter 11 allows debtors to reorganize or liquidate according to a plan. A plan is not effective unless the court confirms it. You may receive a copy of the plan and a disclosure statement telling you about the plan, and you may have the opportunity to vote on the plan. You will receive notice of the date of the confirmation hearing, and you may object to confirmation of the plan and attend the confirmation hearing. Unless a trustee is serving, the debtor will remain in possession of the property and may continue to operate its business.

**11. Discharge of debts** Confirmation of a chapter 11 plan may result in a discharge of debts, which may include all or part of your debt. See 11 U.S.C. § 1141(d). A discharge means that creditors may never try to collect the debt from the debtor except as provided in the plan. If you want to have a particular debt owed to you excepted from the discharge and § 523(c) applies to your claim, you must start a judicial proceeding by filing a complaint and paying the filing fee in the bankruptcy clerk's office by the deadline.

**If you have questions about this notice, please contact the Debtors' Claims and Noticing Agent, Kurtzman Carson Consultants LLC, at (888) 733-1544 (U.S./Canada) or (310) 751-2638 (international), or by email at <http://www.kccllc.net/Eiger/inquiry>.**

**You may also find more information at [www.kccllc.net/Eiger](http://www.kccllc.net/Eiger).**

In re:  
Eiger BioPharmaceuticals, Inc.  
Debtor

Case No. 24-80040-sgj  
Chapter 11

## CERTIFICATE OF NOTICE

District/off: 0539-8  
Date Rcvd: Apr 05, 2024

User: admin  
Form ID: pdf025

Page 1 of 4  
Total Noticed: 7

The following symbols are used throughout this certificate:

**Symbol**      **Definition**

+      Addresses marked '+' were corrected by inserting the ZIP, adding the last four digits to complete the zip +4, or replacing an incorrect ZIP. USPS regulations require that automation-compatible mail display the correct ZIP.

**Notice by first class mail was sent to the following persons/entities by the Bankruptcy Noticing Center on Apr 07, 2024:**

<b>Recip ID</b>	<b>Recipient Name and Address</b>
db	+ Eiger BioPharmaceuticals, Inc., 2155 Park Boulevard, Palo Alto, CA 94306-1543
aty	+ Clifford W. Carlson, Weil, Gotshal & Manges LLP, 700 Louisiana Street, Suite 3700, Houston, TX 77002-2784
aty	+ Emma S. Wheeler, Weil, Gotshal & Manges LLP, 700 Louisiana Street, Suite 3700, Houston, TX 77002-2784
aty	+ James A Newton, Morrison Foerster, 250 West 55th Street, New York, NY 10019-0050
aty	+ Sean Daly, Morrison Foerster, 250 West 55th Street, New York, NY 10019-0050
cr	+ Dr. Colleen Craig Kaludzinski, 144 Costa Rica Avenue, Burlingame, CA 94010-5212
cr	+ INNOVATUS LIFE SCIENCES LENDING FUND I, LP, c/o Bradley, Attn: Jay R. Bender, 214 North Tryon Street, Suite 3700 Charlotte, NC 28202-2671

TOTAL: 7

**Notice by electronic transmission was sent to the following persons/entities by the Bankruptcy Noticing Center.**

Electronic transmission includes sending notices via email (Email/text and Email/PDF), and electronic data interchange (EDI).

NONE

## BYPASSED RECIPIENTS

The following addresses were not sent this bankruptcy notice due to an undeliverable address, \*duplicate of an address listed above, \*P duplicate of a preferred address, or ## out of date forwarding orders with USPS.

NONE

## NOTICE CERTIFICATION

I, Gustava Winters, declare under the penalty of perjury that I have sent the attached document to the above listed entities in the manner shown, and prepared the Certificate of Notice and that it is true and correct to the best of my information and belief.

**Meeting of Creditor Notices only (Official Form 309): Pursuant to Fed .R. Bank. P.2002(a)(1), a notice containing the complete Social Security Number (SSN) of the debtor(s) was furnished to all parties listed. This official court copy contains the redacted SSN as required by the bankruptcy rules and the Judiciary's privacy policies.**

Date: Apr 07, 2024

Signature:           /s/Gustava Winters          

## CM/ECF NOTICE OF ELECTRONIC FILING

The following persons/entities were sent notice through the court's CM/ECF electronic mail (Email) system on April 5, 2024 at the address(es) listed below:

<b>Name</b>	<b>Email Address</b>
Anne G. Wallace	on behalf of Debtor Eiger BioPharmaceuticals Inc. anne.wallice@sidley.com, anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com
Anne G. Wallace	on behalf of Debtor EBPI Merger Inc. anne.wallice@sidley.com anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com
Anne G. Wallace	on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. anne.wallice@sidley.com

District/off: 0539-8  
Date Rcvd: Apr 05, 2024

User: admin  
Form ID: pdf025

Page 2 of 4  
Total Noticed: 7

anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com

Anne G. Wallice

on behalf of Debtor Eiger BioPharmaceuticals Europe Limited anne.wallice@sidley.com  
anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com

Anne G. Wallice

on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited anne.wallice@sidley.com  
anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com

Anne G. Wallice

on behalf of Debtor EigerBio Europe Limited anne.wallice@sidley.com  
anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com

Anne G. Wallice

on behalf of Jointly Administered Party/Debtor EB Pharma LLC anne.wallice@sidley.com  
anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com

Anne G. Wallice

on behalf of Jointly Administered Party/Debtor Eiger BioPharmaceuticals Europe Limited anne.wallice@sidley.com  
anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com

Anne G. Wallice

on behalf of Debtor EB Pharma LLC anne.wallice@sidley.com anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com

Bruce H White

on behalf of Creditor Dr. Colleen Craig Kaludzinski bwhite@parsonsbehle.com

Candice Marie Carson

on behalf of Creditor Eton Pharmaceuticals Inc. Candice.Carson@butlersnow.com

Charles Martin Persons, Jr.

on behalf of Debtor Eiger BioPharmaceuticals Inc. cpersons@sidley.com,  
txefilingnotice@sidley.com;charles-persons-5722@ecf.pacerpro.com

Jay Robert Bender

on behalf of Creditor INNOVATUS LIFE SCIENCES LENDING FUND I LP jrbender@bradley.com

Lawrence James Dickinson

on behalf of Interested Party Sentynl Therapeutics Inc. james.dickinson@pillsburylaw.com,  
nancy.jones@pillsburylaw.com;docket@pillsburylaw.com

Martin A. Sosland

on behalf of Creditor Eton Pharmaceuticals Inc. martin.sosland@butlersnow.com,  
ecf.notices@butlersnow.com,velvet.johnson@butlersnow.com

Nathan Elner

on behalf of Debtor Eiger BioPharmaceuticals Inc. nelner@sidley.com

Nathan Elner

on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. nelner@sidley.com

Nathan Elner

on behalf of Debtor Eiger BioPharmaceuticals Europe Limited nelner@sidley.com

Nathan Elner

on behalf of Jointly Administered Party/Debtor Eiger BioPharmaceuticals Europe Limited nelner@sidley.com

Nathan Elner

on behalf of Jointly Administered Party/Debtor EB Pharma LLC nelner@sidley.com

Nathan Elner

on behalf of Debtor EB Pharma LLC nelner@sidley.com

Nathan Elner

on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited nelner@sidley.com

Nathan Elner

on behalf of Debtor EBPI Merger Inc. nelner@sidley.com

Nathan Elner

on behalf of Debtor EigerBio Europe Limited nelner@sidley.com

Roger G. Jones

on behalf of Creditor INNOVATUS LIFE SCIENCES LENDING FUND I LP rjones@bradley.com

Thomas Robert Califano

on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. tom.califano@sidley.com  
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Thomas Robert Califano

on behalf of Debtor Eiger BioPharmaceuticals Europe Limited tom.califano@sidley.com  
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

District/off: 0539-8  
Date Rcvd: Apr 05, 2024

User: admin  
Form ID: pdf025

Page 3 of 4  
Total Noticed: 7

Thomas Robert Califano

on behalf of Debtor EB Pharma LLC tom.califano@sidley.com  
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Thomas Robert Califano

on behalf of Jointly Administered Party/Debtor Eiger BioPharmaceuticals Europe Limited tom.califano@sidley.com  
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Thomas Robert Califano

on behalf of Debtor EBPI Merger Inc. tom.califano@sidley.com  
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Thomas Robert Califano

on behalf of Debtor Eiger BioPharmaceuticals Inc. tom.califano@sidley.com,  
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Thomas Robert Califano

on behalf of Jointly Administered Party/Debtor EB Pharma LLC tom.califano@sidley.com  
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Thomas Robert Califano

on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited tom.califano@sidley.com  
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Thomas Robert Califano

on behalf of Debtor EigerBio Europe Limited tom.califano@sidley.com  
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

United States Trustee

ustpreion06.da.ecf@usdoj.gov

Veronica A. Courtney

on behalf of Debtor EigerBio Europe Limited vcourtney@sidley.com  
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney

on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. vcourtney@sidley.com  
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney

on behalf of Jointly Administered Party/Debtor EB Pharma LLC vcourtney@sidley.com  
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney

on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited vcourtney@sidley.com  
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney

on behalf of Debtor EB Pharma LLC vcourtney@sidley.com  
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney

on behalf of Debtor EBPI Merger Inc. vcourtney@sidley.com  
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney

on behalf of Debtor Eiger BioPharmaceuticals Europe Limited vcourtney@sidley.com  
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney

on behalf of Jointly Administered Party/Debtor Eiger BioPharmaceuticals Europe Limited vcourtney@sidley.com  
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney

on behalf of Debtor Eiger BioPharmaceuticals Inc. vcourtney@sidley.com,  
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

William E Curtin

on behalf of Jointly Administered Party/Debtor EB Pharma LLC wcurtin@sidley.com  
william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

on behalf of Debtor EB Pharma LLC wcurtin@sidley.com william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

on behalf of Debtor EigerBio Europe Limited wcurtin@sidley.com  
william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. wcurtin@sidley.com  
william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

District/off: 0539-8

User: admin

Page 4 of 4

Date Rcvd: Apr 05, 2024

Form ID: pdf025

Total Noticed: 7

on behalf of Debtor Eiger BioPharmaceuticals Europe Limited wcurtin@sidley.com  
william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

on behalf of Debtor EBPI Merger Inc. wcurtin@sidley.com william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

on behalf of Debtor Eiger BioPharmaceuticals Inc. wcurtin@sidley.com,  
william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

on behalf of Jointly Administered Party/Debtor Eiger BioPharmaceuticals Europe Limited wcurtin@sidley.com  
william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited wcurtin@sidley.com  
william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

TOTAL: 53